Archive

2013, Vol. 123, No. 5

May 29, 2013

previous issuenext issue
Editorials
β‑blockers in heart failure – are all created equal?

Romina Brignardello-Petersen, Gordon H. Guyatt

Pol Arch Intern Med. 2013, Vol. 123, No. 5: 204-205 / DOI: 10.20452/pamw.1720

Original articles
Do primary care physicians follow the current recommendations for hypertensive pharmacotherapy?

Agnieszka Żak‑Gołąb, Michał Holecki, Mike Smertka, Jerzy Chudek

Pol Arch Intern Med. 2013, Vol. 123, No. 5: 206-214 / DOI: 10.20452/pamw.1722

Assessment of leptin and resistin levels in patients with chronic obstructive pulmonary disease

Anna Kumor‑Kisielewska, Dorota Kierszniewska‑Stępień, Tadeusz Pietras, Jadwiga Kroczyńska‑Bednarek, Zofia Kurmanowska, Adam Antczak, Paweł Górski

Pol Arch Intern Med. 2013, Vol. 123, No. 5: 215-220 / DOI: 10.20452/pamw.1724

Safety of enhanced renin–angiotensin–aldosterone system inhibition with aliskiren in nondiabetic patients with chronic kidney disease

Sławomir Lizakowski, Leszek Tylicki, Przemysław Rutkowski, Marcin Renke, Beata Sulikowska, Zbigniew Heleniak, Rafał Donderski, Rafał Bednarski, Milena Przybylska, Jacek Manitius, Bolesław Rutkowski

Pol Arch Intern Med. 2013, Vol. 123, No. 5: 221-227 / DOI: 10.20452/pamw.1726

Role of preprocedural glutathione concentrations in the prediction of major adverse cardiac events in patients with acute coronary syndrome treated with percutaneous coronary intervention

Robert Pietruszyński, Leszek Markuszewski, Konrad Masiarek, Marcin Makowski, Weronika Retelewska, Cezary Watala

Pol Arch Intern Med. 2013, Vol. 123, No. 5: 228-237 / DOI: 10.20452/pamw.1728

One‑year follow‑up of the Polish subset of the RecordAF registry of patients with newly diagnosed atrial fibrillation

Grzegorz Opolski, Dariusz A. Kosior, Michał Kurzelewski, Günter Breithardt; the Polish RecordAF Investigators

Pol Arch Intern Med. 2013, Vol. 123, No. 5: 238-245 / DOI: 10.20452/pamw.1730

Review articles
New horizons in allergy diagnostics and treatment

Rafał Pawliczak

Pol Arch Intern Med. 2013, Vol. 123, No. 5: 246-250 / DOI: 10.20452/pamw.1732

Clinical images
Multiple skin lesions caused by imatinib mesylate treatment of chronic myeloid leukemia

Maciej Machaczka, Maria Gossart

Pol Arch Intern Med. 2013, Vol. 123, No. 5: 251-252 / DOI: 10.20452/pamw.1734

Cardiac involvement in hypereosinophilic syndrome

Tomasz Miszalski‑Jamka, Wojciech Szczeklik, Barbara Sokołowska, Krzysztof Karwat, Przemysław Jaźwiec, Jacek Musiał

Pol Arch Intern Med. 2013, Vol. 123, No. 5: 253-254 / DOI: 10.20452/pamw.1736

Unusual case of phosphaturic mesenchymal tumor

Lucyna Papierska, Jarosław B, Ćwikła, Waldemar Misiorowski, Michał Rabijewski, Krzysztof Sikora, Hubert Wanyura

Pol Arch Intern Med. 2013, Vol. 123, No. 5: 255-256 / DOI: 10.20452/pamw.1738

Letters to the Editor
Bone marrow suppression with plasma cell leukemia‑like reaction complicated by macrophage activation syndrome after metamizole overuse

Artur Jurczyszyn, Anna Engel, Stanisława Bazan-Socha, Jacek Czepiel, Grażyna Biesiada, Aleksander B. Skotnicki

Pol Arch Intern Med. 2013, Vol. 123, No. 5: 257-258 / DOI: 10.20452/pamw.1740

Tamoxifen as the possible cause of severe thromboembolic complications in a patient with a history of renal transplantation and encapsulating peritoneal sclerosis: authors' reply

Tomasz Jakimowicz, Ewa Wojtaszek, Titus Augustine, Agnieszka Grzejszczak, Joanna Matuszkiewicz-Rowińska

Pol Arch Intern Med. 2013, Vol. 123, No. 5: 259-261 / DOI: 10.20452/pamw.1744

Tamoxifen as the possible cause of severe thromboembolic complications in a patient with a history of renal transplantation and encapsulating peritoneal sclerosis

Anna Pawłowska, Bogna Kwella, Józef Kozak, Grzegorz Wasilewski, Tomasz Stompór

Pol Arch Intern Med. 2013, Vol. 123, No. 5: 259-261 / DOI: 10.20452/pamw.1742

Impact Factor 2022

4.8

IC value for 2022

217.18

Ministry of Education and Science score

200
Average times from:
submission to 1st decision, 2 days
submission to first reviews, 23 days
acceptance to online first publication, 7 days
acceptance to final publication, 91 days

Current manuscript acceptance rate: 28%
The journal is co-financed from the state budget under the "Development of scientific journals" program of the Ministry of Education and Science in the years 2022-2024. Read more